Ticker Details
CytomX Therapeutics, Inc. CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.
IPO Date:	October 8, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$818.56M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.24 | 3.05%
Avg Daily Range (30 D):	$0.09 | 2.14%
Avg Daily Range (90 D):	$0.18 | 3.52%

Institutional Daily Volume
Avg Daily Volume:	1.1M
Avg Daily Volume (30 D):	2.89M
Avg Daily Volume (90 D):	5.16M

Trade Size
Avg Trade Size (Sh.):	196
Avg Trade Size (Sh.) (30 D):	145
Avg Trade Size (Sh.) (90 D):	169

Institutional Trades
Total Institutional Trades:	1,178
Avg Institutional Trade:	$1.56M
Avg Institutional Trade (30 D):	$2.04M
Avg Institutional Trade (90 D):	$2.04M
Avg Institutional Trade Volume:	.25M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.73M
Avg Closing Trade (30 D):	$2.35M
Avg Closing Trade (90 D):	$2.13M
Avg Closing Volume:	256.11K

News

May 21, 2026 @ 12:00 PM CytomX Therapeutics to Present at Upcoming June In... Source: Not Specified

Apr 22, 2026 @ 10:28 PM Small Cap or Megacap: Which Healthcare Stock Is Ri... Source: Jack Delaney

Mar 18, 2026 @ 2:46 AM CytomX Therapeutics Announces Pricing of $250 Mill... Source: Cytomx Therapeutics, Inc.

Feb 4, 2026 @ 1:00 PM CytomX Therapeutics to Present at Upcoming Februar... Source: Not Specified

Nov 13, 2025 @ 1:00 PM CytomX Therapeutics to Present at the Jefferies Lo... Source: Cytomx Therapeutics

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS
Diluted EPS
Revenue	$35.54M	$10.26M	$.66M
Gross Profit
Net Income / Loss	$-59.14M	$-18.25M	$-26.51M
Operating Income / Loss	$-64.66M	$-19.67M	$-27.93M
Cost of Revenue
Net Cash Flow	$-8.72M	$16.16M	$-21.02M
PE Ratio